CD274 and neoplasm: Although PD-L1 expression, tumor mutational burden (TMB) and tumor-infiltrating lymphocyte density have been reported to predict the efficacy of immune checkpoint inhibitor antibodies in CRC, the predictive value of these biomarkers remains controversial [14, 15].